Patients with category II or III risk of coronary artery disease ( CAD ) , or those with a history of CAD ( secondary prevention ) , who had not achieved their JAS@GL LDL-C goals during treatment with atorvastatin for at least @ weeks were switched either to rosuvastatin @ mg/day ( from atorvastatin @ mg/day ) or rosuvastatin @ mg/day ( from atorvastatin @ mg/day ) ( n = @ ) or continued to receive atorvastatin ( n = @ ) .